Online citations, reference lists, and bibliographies.
← Back to Search

Sustainability Of Eribulin Treatment For Patients With Metastatic Breast Cancer: Is The Cost Of The Drug Related To The Benefit Produced (Effectiveness And Safety)? A Single Center Experience

Garipoli Claudia, D. Alessandro, A. Nicolò
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Objective:To report the clinical outcomes and health care costs of Metastatic Breast Cancer patients treated with Eribulin, in the Medical Oncology Unit of the Messina University. Method:We retrospectively analyzed the costs associated  with eribulin treatment in 15 MBC patients from January 2014 to December 2016  at  Messina University Hospital. The PFS , ORR , DCR and the average cost of patient therapy were calculated. Result:15 patients were included in this analysis. They had received a median of 4 lines of therapy previously (including adjuvant treatment) and had significant visceral involvement (median 3 organs). A median of 4 cycles of eribulin was delivered. There were partial responses  in 20% patients , stable disease status in 14% , and progressive disease in 66% . The median progression-free survival was 15 weeks (3.5 months), ORR was 20%, DCR was 33%  . The most frequent treatment-related  adverse events were neutropenia (26%), and febrile neutropenia (20%). Therapy for these patients resulted in a cost of euros 158.244,76. Assessing the repayment by the pharmaceutical company equals to euros 20.238,37  for non –responders patients , there is a net cost of euros 138.006,39. Conclusion: Our results have shown that treatment with eribulin  applied to patients pretreated in III / IV metastatic line and beyond, so the high percentage of non-responders is determined because of the already expired general conditions at the beginning of treatment. Despite this ,eribulin was shown to be an effective and safe therapeutic option in heavily pretreated patients with MBC. The costs associated with eribulin therapy have shown that payment by result contributes to making the cost of therapy more sustainable by the National Health Service
This paper references
10.1007/978-0-387-74039-3_1
Overview of resistance to systemic therapy in patients with breast cancer.
A. González-Angulo (2007)
10.1097/00001813-199902000-00003
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
K. Possinger (1999)
10.1016/S0084-3873(11)00184-2
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
J. Thigpen (2011)
10.1016/S1470-2045(11)70141-3
Delivering affordable cancer care in high-income countries.
R. Sullivan (2011)
10.1186/1471-2407-11-373
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
10.1093/annonc/mdr444
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.
K. Aogi (2012)
10.1007/s10549-012-2097-2
The economic burden of metastatic breast cancer: a U.S. managed care perspective
A. Montero (2012)
10.1200/JCO.2013.52.4892
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
P. Kaufman (2015)
10.1016/S1470-2045(07)70041-4
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
M. Martín (2007)
3 rd ESO ‐ ESMO international consensus guidelines for advanced breast cancer ( ABC 3 ) . ( Published erratum appears in Breast 2017 ; 32 : 269 – 70
F Cardoso
10.1016/j.breast.2016.10.001
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).
F. Cardoso (2017)
10.1186/1471-2407-11-250
Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
M. Vera-Llonch (2010)
10.1093/annonc/mdr024
Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.
M. Martín (2011)
10.1016/S0305-7372(03)00139-7
Platinum-based chemotherapy in metastatic breast cancer: current status.
M. Decatris (2004)
10.1007/s10549-011-1919-y
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
A. Montero (2011)
10.1093/jnci/djq029
International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
O. Pagani (2010)
10.7150/jca.8748
Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
T. Gamucci (2014)
Economic/societal burden of metastatic breast cancer: a US perspective.
J. Allen (2010)
10.1634/theoncologist.2009-0078
Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy.
V. Guarneri (2009)
10.1007/s10549-007-9550-7
Impact of chemotherapy beyond the first line in patients with metastatic breast cancer
A. Dufresne (2007)
10.1016/j.ctrv.2010.12.008
The economic burden of metastatic breast cancer: a systematic review of literature from developed countries.
T. Foster (2011)



Semantic Scholar Logo Some data provided by SemanticScholar